

SOUTH EAST MOLECULAR SOLID TUMOUR
REQUEST FORM

Request forms from: www.southeastgenomics.nhs.uk

All fields are mandatory. Illegible, unclear or incomplete forms will result in delays or rejection.
 Use separate referral forms for DPYD and WGS. This page is to be printed.

| PATIENT DEMOGRAPHICS | |
|---|--|
| First name: | |
| Last name: | |
| DOB: | Gender: Male <input type="checkbox"/> Female <input type="checkbox"/> Other <input type="checkbox"/> |
| NHS number: | |
| Hospital no: | Postcode: |
| Laboratory Accession no.: | |
| Purchase Order no.: | |
| Non-NHSE funded i.e. Research / Private (attach invoicing details) <input type="checkbox"/> | |
| Ethnicity: | |

| FOR CANCER GENETICS USE |
|-------------------------|
| |

| | | | |
|--|---|---|---|
| Sample from: <input type="checkbox"/> FFPE biopsy <input type="checkbox"/> FFPE resection <input type="checkbox"/> Cell block <input type="checkbox"/> Cytological material (e.g. Giemsa stained slides) <input type="checkbox"/> Other Please specify: _____ | Material sent: <input type="checkbox"/> Control sample normal tissue or PB in EDTA <input type="checkbox"/> DNA _____ ng/μl <input type="checkbox"/> curls/scrolls >20% tumour; 5x10μm sections <input type="checkbox"/> slides <20% tumour; 5x10μm sections plus marked H&E slide <input type="checkbox"/> slides for FISH; 3x4μm sections plus H&E/immuno | Tumour sample % Tumour Cellularity (or % neoplastic cells): _____ <input type="checkbox"/> Primary <input type="checkbox"/> Metastatic Biopsy or resection <input type="checkbox"/> Biopsy site: _____ Sample collection date & time | Remarks: Necrosis: Yes <input type="checkbox"/> No <input type="checkbox"/> High pigmentation: Yes <input type="checkbox"/> No <input type="checkbox"/> >48 hour fixation time: Yes <input type="checkbox"/> No <input type="checkbox"/> Rapid fixation time: Yes <input type="checkbox"/> No <input type="checkbox"/> Decal: Yes <input type="checkbox"/> No <input type="checkbox"/> (if yes: EDTA <input type="checkbox"/> Formic Acid <input type="checkbox"/> Please refer to the GLH website for guidance on tissue pathways. |
|--|---|---|---|

| TEST DIRECTORY CLINICAL INDICATION & CODE | |
|---|---|
| M Code: Test Code: | Other solid tumour requests <input type="checkbox"/> Please discuss with the lab before sending the sample Please specify tumour type and genes for analysis: |

| CLINICIAN DETAILS | |
|--|---|
| Requesting Clinician / Consultant: Hospital & Department: E-mail (for contact and reports): Phone: Signature: _____ Date: ___ / ___ / ___ Histopathologist: Histopathologist e-mail for contact: | CLINICAL DETAILS (Diagnosis/Reason for Referral): Tumour Type: Histological Subtype: |

| |
|---|
| Additional clinical information (if required) <i>E.g. previous tumours, molecular testing, and relevant treatment history with date(s)</i> |
|---|

Please send all samples to: Cancer Genetics, Genetics Laboratories, 5th Floor Tower Wing, Guy's Hospital, London SE1 9RT
 Please attach a copy of the histopathology report if relevant.

In submitting this form, the clinician confirms that consent has been obtained for testing and storage.

All fields are mandatory. Illegible, unclear or incomplete forms will result in delays or rejection.
Use separate referral forms for DPYD and WGS.

Please indicate the relevant clinical indication and code on page 1.

| CI Code | Clinical Indication Name | | | |
|---------|----------------------------|--------|---|--|
| M1 | Colorectal Carcinoma | M1.1 | Multi-target NGS panel - small variant (KRAS, NRAS, BRAF) | |
| M1 | Colorectal Carcinoma | M1.4 | MSI Testing | |
| M1 | Colorectal Carcinoma | M1.5 | MLH1 promoter hypermethylation | |
| M1 | Colorectal Carcinoma | M1.6 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M1 | Colorectal Carcinoma | M1.9 | Multi-target NGS panel - small variant (MLH1, MSH2, MSH6, PMS2, POLD1, POLE) | |
| M2 | Ovarian Carcinoma | M2.1 | Multi-target NGS panel - small variant (BRCA1, BRCA2, SMARCA4) | |
| M2 | Ovarian Carcinoma | M2.3 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M2 | Ovarian Carcinoma | M2.5 | HRD status (either positive for BRCA1 and/or 2, or HRD positive) - please complete separate HRD referral form | |
| M215 | Endometrial Cancer | M215.1 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M215 | Endometrial Cancer | M215.2 | MLH1 promoter hypermethylation | |
| M215 | Endometrial Cancer | M215.4 | Multi-target NGS panel - small variant (MLH1, MSH2, MSH6, PMS2) | |
| M215 | Endometrial Cancer | M215.5 | Multi-target NGS panel-small variant detection POLE | |
| M3 | Breast Cancer | M3.5 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M3 | Breast Cancer | M3.6 | Multi-target NGS panel - small variant (PIK3CA) | |
| M3 | Breast Cancer | M3.9 | ETV6-NTRK3 FISH/RT-PCR | |
| M4 | Non-Small Cell Lung Cancer | M4.1 | Multi-target NGS panel - small variant (EGFR, ALK, BRAF, KRAS, MET) | |
| M4 | Non-Small Cell Lung Cancer | M4.2 | Multi-target NGS panel - structural variant (ROS1, RET, EML4-ALK, NTRK1, NTRK1, NTRK3, MET) | |
| M4 | Non-Small Cell Lung Cancer | M4.3 | Multi-target NGS panel - copy number variant (MET) | |
| M4 | Non-Small Cell Lung Cancer | M4.6 | ROS1 rearrangement FISH/RT-PCR | |
| M4 | Non-Small Cell Lung Cancer | M4.7 | RET rearrangement FISH/RT-PC | |
| M4 | Non-Small Cell Lung Cancer | M4.8 | MET copy number FISH | |
| M4 | Non-Small Cell Lung Cancer | M4.10 | EML4-ALK FISH/RT-PCR | |
| M231 | Small cell lung cancer | M231.2 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M5 | Mesothelioma | M5.1 | CDKN2A copy number FISH | |
| M5 | Mesothelioma | M5.2 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M6 | Mucoepidermoid Carcinoma | M6.1 | MAML2 rearrangement FISH | |
| M6 | Mucoepidermoid Carcinoma | M6.2 | Multi-target NGS panel - structural variant (MAML2, NTRK1, NTRK2, NTRK3) | |
| M6 | Mucoepidermoid Carcinoma | M6.3 | Multi-target NGS panel - structural variant (MAML2) | |
| M7 | Melanoma - Adult | M7.1 | Multi-target NGS panel - small variant (BRAF, KIT, NRAS) | |
| M7 | Melanoma - Adult | M7.3 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M7 | Melanoma - Adult | M7.5 | MYB & 6cen | |
| M7 | Melanoma - Adult | M7.6 | RREB1 (6p25) | |
| M7 | Melanoma - Adult | M7.7 | CCND1 (11q13) | |

Please send all samples to: Cancer Genetics, Genetics Laboratories, 5th Floor Tower Wing, Guy's Hospital, London SE1 9RT
Please attach a copy of the histopathology report if relevant.

In submitting this form, the clinician confirms that consent has been obtained for testing and storage.

All fields are mandatory. Illegible, unclear or incomplete forms will result in delays or rejection.
Use separate referral forms for DPYD and WGS.

Please indicate the relevant clinical indication and code on page 1.

| | | | | |
|------|---|--------|--|--|
| M7 | Melanoma - Adult | M7.9 | CDKN2A & 9cen | |
| M241 | Conjunctival melanoma | M241.1 | MYB & 6cen | |
| M241 | Conjunctival melanoma | M241.2 | RREB1 (6p25) | |
| M241 | Conjunctival melanoma | M241.3 | CCND1 (11q13) | |
| M241 | Conjunctival melanoma | M241.5 | CDKN2A & 9cen | |
| M187 | Uveal melanoma | M187.3 | Multi-target NGS panel - small variant (BRAF, NRAS, NF1) | |
| M187 | Uveal melanoma | M187.4 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M8 | Gastrointestinal Stromal Tumour | M8.1 | Multi-target NGS panel - small variant (KIT, PDGFRA) | |
| M8 | Gastrointestinal Stromal Tumour | M8.2 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M9 | Thyroid Papillary Carcinoma - Adult | M9.1 | Multi-target NGS panel - small variant (BRAF, KRAS, NRAS, HRAS, TERT promoter) | |
| M9 | Thyroid Papillary Carcinoma - Adult | M9.2 | Multi-target NGS panel - structural variant (RET, NTRK1, NTRK2, NTRK3) | |
| M9 | Thyroid Papillary Carcinoma - Adult | M9.3 | RET rearrangement FISH/RT-PC | |
| M9 | Thyroid Papillary Carcinoma - Adult | M9.4 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M10 | Thyroid Follicular Carcinoma | M10.1 | Multi-target NGS panel - small variant (KRAS, NRAS, HRAS) | |
| M10 | Thyroid Follicular Carcinoma | M10.2 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3, RET) | |
| M11 | Poorly Differentiated Anaplastic Thyroid Carcinoma | M11.1 | Multi-target NGS panel - small variant (TP53, BRAF) | |
| M11 | Poorly Differentiated Anaplastic Thyroid Carcinoma | M11.4 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3, RET, ALK) | |
| M12 | Thyroid Medullary Carcinoma | M12.1 | Multi-target NGS panel - small variant (RET) | |
| M12 | Thyroid Medullary Carcinoma | M12.2 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M239 | Thyroid Hurtle Cell Carcinoma | M239.1 | Multi-target NGS panel - structural variant (RET) | |
| M240 | Non-invasive follicular thyroid neoplasm with papillary like nuclei | M240.1 | Multi-target NGS panel - small variant (BRAF,HRAS,NRAS,KRAS) | |
| M13 | Phaeochromocytoma | M13.1 | Multi-target NGS panel - small variant (RET) | |
| M13 | Phaeochromocytoma | M13.2 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M14 | Adrenal Cortical Carcinoma | M14.1 | Multi-target NGS panel - small variant (TP53) | |
| M14 | Adrenal Cortical Carcinoma | M14.4 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M15 | Head and Neck Squamous Cell Carcinoma | M15.1 | Multi-target NGS panel - small variant (CDKN2A, EGFR, TP53) | |
| M15 | Head and Neck Squamous Cell Carcinoma | M15.2 | Multi-target NGS panel - structural variant (RET, NTRK1, NTRK2, NTRK3) | |
| M15 | Head and Neck Squamous Cell Carcinoma | M15.4 | RET rearrangement FISH/RT-PC | |
| M15 | Head and Neck Squamous Cell Carcinoma | M15.6 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M16 | Adenoid Cystic Carcinoma | M16.1 | MYB-NFIB FISH/RT-PCR | |
| M16 | Adenoid Cystic Carcinoma | M16.2 | Multi-target NGS panel - structural variant (MYB-NFIB, NTRK1, NTRK2, NTRK3) | |
| M17 | Secretory Carcinoma (Salivary Gland) | M17.1 | ETV6-NTRK3 FISH/RT-PCR | |

Please send all samples to: Cancer Genetics, Genetics Laboratories, 5th Floor Tower Wing, Guy's Hospital, London SE1 9RT
Please attach a copy of the histopathology report if relevant.

In submitting this form, the clinician confirms that consent has been obtained for testing and storage.

All fields are mandatory. Illegible, unclear or incomplete forms will result in delays or rejection.
Use separate referral forms for DPYD and WGS.

Please indicate the relevant clinical indication and code on page 1.

| | | | | |
|------|---|--------|--|--|
| M17 | Secretory Carcinoma (Salivary Gland) | M17.2 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M18 | Renal Cell Carcinoma - Adult | M18.1 | TFE3 rearrangement FISH/RT-PCR | |
| M18 | Renal Cell Carcinoma - Adult | M18.2 | Multi-target NGS panel small variant (FH, SDHA, SDHB, SDHC, SDHD, VHL, ELOC (TCEB-1), TSC1/2, MET, BRAF) | |
| M18 | Renal Cell Carcinoma - Adult | M18.6 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3, TFE3, TFEB) | |
| M217 | Bladder Cancer | M217.1 | Multi-target NGS panel - small variant (FGFR3, FGFR2) | |
| M217 | Bladder Cancer | M217.3 | Multi-target NGS panel - structural variant (FGFR3, FGFR2, NTRK1, NTRK2, NTRK3) | |
| M218 | Prostate Cancer | M218.1 | Multi-target NGS panel - small variant (BRCA1, BRCA2) | |
| M218 | Prostate Cancer | M218.2 | Multi-target NGS panel - structural variant (TMPRSS2-ERG, NTRK1, NTRK2, NTRK3) | |
| M219 | Pancreatic Cancer | M219.1 | Multi-target NGS panel - small variant (BRCA1, BRCA2) | |
| M219 | Pancreatic Cancer | M219.2 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M219 | Pancreatic Cancer | M219.5 | MSI Testing | |
| M220 | Cholangiocarcinoma | M220.1 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3, FGFR2) | |
| M220 | Cholangiocarcinoma | M220.5 | MSI Testing | |
| M220 | Cholangiocarcinoma | M220.6 | Multi-target NGS panel -small variant (IDH1) | |
| M220 | Cholangiocarcinoma | M220.7 | FISH | |
| M221 | Spitzoid tumour | M221.1 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M222 | Hepatocellular carcinoma | M222.2 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M226 | Cancer of Unknown Primary | M226.1 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M227 | Solid tumour other (i.e. specific histology not listed elsewhere in the test directory) | M227.1 | Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3) | |
| M236 | Oesophageal Cancer | M236.1 | MSI Testing | |
| M237 | Gastric Cancer | M237.1 | MSI Testing | |
| M238 | Small Bowel Cancer | M238.1 | MSI Testing | |
| M243 | Thymic Carcinoma | M243.1 | Multi-target NGS panel (KIT) | |
| M244 | In all tumours eligible for NTRK1/2/3 testing | M244.1 | FISH | |
| M245 | Ovarian sex cord stromal tumours | M245.1 | Multi-target NGS panel - FOXL1, CTNNB1, APC, DICER1 | |

Please send all samples to: Cancer Genetics, Genetics Laboratories, 5th Floor Tower Wing, Guy's Hospital, London SE1 9RT
Please attach a copy of the histopathology report if relevant.

In submitting this form, the clinician confirms that consent has been obtained for testing and storage.